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Introduction

Results: Colorectal Cancer Screening

• Colorectal (CRC) and breast cancer (BC) are two of
the most diagnosed cancers in the United States.
They make up an estimated 431,000 new cases
and an estimated 96,580 deaths, combined1.
• Screening for these cancers is essential to
diagnosing them early and improving a patient’s
prognosis.
• Routine cancer screenings were postponed to limit
potential spread of the SARS-CoV2 virus2.
• Current research examining the effect of the
COVID-19 pandemic on CRC and BC screening is
limited to specific methods or is within a narrow time
frame.

• We observed a significant declining trend in the overall
CRC screening rates from 2019 Q1 to 2020 Q2 over six
quarters (p<0.001). Fig.1 (A)
• We observed a 47% decrease in overall CRC
screening in Q2 2020 compared to Q4 2019 (p<0.001).
Fig.1 (A) *
• We also observed a significant declining trend for
colonoscopy, stool-based CRC screening tests,
sigmoidoscopy, and CT Colonography over the same
period. Fig.1 (B-E)
• When stratifying the data by race, the declining trend
remained consistent and significant across Asian,
Black, Hispanic, and White patients for overall CRC
screening. Fig.2

Objectives

Results: Breast Cancer Screening
• We observed a significant declining trend in the
overall BC screening rates from 2019 Q1 to 2020
Q2 over six quarters (p<0.001). Fig.3
• We observed a 50% decrease in overall BC
screening in Q2 2020 compared to Q4 2019
(p<0.001). Fig.3 *
• When stratifying the data by race, the declining
trend remained consistent across Asian (A), Black
(B), Hispanic (H), and White (W) patients for
overall BC screening (p<0.001). Fig.4

*

(A)

• To analyze how the rates of overall CRC and BC
screening varied between 2019 through 2020; and,
to determine how both rates varied across patient
populations.

*

*

*

Methods
Figure 3. Overall BC screening rate over six quarters (p<0.001)

• Selecting our cohort:
Sourced CRC and BC screening claims data from
the OPTUM® claims database

Colonoscopy
(B)

Sigmoidoscopy
(D)

Identified 8,656,406 eligible* CRC screening
and 5,116,717 eligible BC screening patients
in 2019 through 2020
CT Colonography

Stool-based CRC Screening
(C)

(E)

Figure 4. BC screening rate by race; A: Asian, B: Black, H: Hispanic, W: White

Determined screening rate per quarter:

Conclusions

No screenings per quarter
No eligible patients per quarter

* Eligibility was defined as patients fully insured
during an entire quarter and eligible for screening
according to the American Cancer Society: ages
51 - 75 for CRC and women ages 46 - 74 for BC.

Figure 1. (A) Overall CRC screening rate over six quarters (p<0.001); (B)
Colonoscopy rate; (C) Stool-based CRC screening tests rate: fecal
immunochemical test (FIT), fecal occult blood test (FOBT), and stool DNA test
(p<0.001 for all); (D) Sigmoidoscopy rate (p=0.0035); (E) CT Colonography rate
(p=0.0047)

Performed the following statistical tests:
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• Cochran-Armitage trend test to determine the
significance of the change in screening rate
over time.
• Kruskal-Wallis test to compare the screening
rates of specific quarters.

• There was a significant decrease in overall CRC
screening, each CRC screening modality, and BC
screening from Q1 2019 through Q2 2020 across the
United States.
• We also observed a decrease in screening rates by
approximately 50% during Q2 2020 for BC and CRC.
• When stratifying the data by race, the declining trend
remained consistent across patient races for overall
CRC screening, each CRC screening modality, and
BC screening.

Figure 2. CRC screening rate by race; A: Asian, B: Black, H: Hispanic, W: White
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